1. Home
  2. ATOM vs ADCT Comparison

ATOM vs ADCT Comparison

Compare ATOM & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atomera Incorporated

ATOM

Atomera Incorporated

HOLD

Current Price

$3.99

Market Cap

157.7M

Sector

Technology

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.23

Market Cap

136.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATOM
ADCT
Founded
2001
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.7M
136.1M
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
ATOM
ADCT
Price
$3.99
$1.23
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.75
AVG Volume (30 Days)
422.3K
1.8M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
4.41
30.86
EPS
N/A
N/A
Revenue
$62,000.00
$81,357,000.00
Revenue This Year
$527.69
N/A
Revenue Next Year
N/A
$66.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.85
52 Week Low
$1.89
$0.78
52 Week High
$12.37
$4.98

Technical Indicators

Market Signals
Indicator
ATOM
ADCT
Relative Strength Index (RSI) N/A 54.06
Support Level N/A $1.03
Resistance Level N/A $1.45
Average True Range (ATR) 0.00 0.08
MACD 0.00 0.03
Stochastic Oscillator 0.00 68.94

Price Performance

Historical Comparison
ATOM
ADCT

About ATOM Atomera Incorporated

Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: